172 related articles for article (PubMed ID: 23354306)
1. CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.
Kim DJ; Lee MH; Reddy K; Li Y; Lim DY; Xie H; Lee SY; Yeom YI; Bode AM; Dong Z
Carcinogenesis; 2013 May; 34(5):1134-43. PubMed ID: 23354306
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
[TBL] [Abstract][Full Text] [Related]
3. Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade.
Kim PN; Jonasch E; Mosterman BC; Mier JW; Janssen RA
Cell Growth Differ; 2001 Nov; 12(11):543-50. PubMed ID: 11714635
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.
Daouti S; Wang H; Li WH; Higgins B; Kolinsky K; Packman K; Specian A; Kong N; Huby N; Wen Y; Xiang Q; Podlaski FJ; He Y; Fotouhi N; Heimbrook D; Niu H
Cancer Res; 2009 Mar; 69(5):1924-32. PubMed ID: 19244124
[TBL] [Abstract][Full Text] [Related]
5. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
7. Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity.
Gysin S; Paquette J; McMahon M
Mol Cancer Res; 2012 Dec; 10(12):1607-19. PubMed ID: 22833572
[TBL] [Abstract][Full Text] [Related]
8. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.
Ishii N; Harada N; Joseph EW; Ohara K; Miura T; Sakamoto H; Matsuda Y; Tomii Y; Tachibana-Kondo Y; Iikura H; Aoki T; Shimma N; Arisawa M; Sowa Y; Poulikakos PI; Rosen N; Aoki Y; Sakai T
Cancer Res; 2013 Jul; 73(13):4050-4060. PubMed ID: 23667175
[TBL] [Abstract][Full Text] [Related]
9. Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.
Senawong T; Phuchareon J; Ohara O; McCormick F; Rauen KA; Tetsu O
Hum Mol Genet; 2008 Feb; 17(3):419-30. PubMed ID: 17981815
[TBL] [Abstract][Full Text] [Related]
10. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
[TBL] [Abstract][Full Text] [Related]
11. The biology and clinical development of MEK inhibitors for cancer.
Luke JJ; Ott PA; Shapiro GI
Drugs; 2014 Dec; 74(18):2111-28. PubMed ID: 25414119
[TBL] [Abstract][Full Text] [Related]
12. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
Iverson C; Larson G; Lai C; Yeh LT; Dadson C; Weingarten P; Appleby T; Vo T; Maderna A; Vernier JM; Hamatake R; Miner JN; Quart B
Cancer Res; 2009 Sep; 69(17):6839-47. PubMed ID: 19706763
[TBL] [Abstract][Full Text] [Related]
13. MEK inhibitor for gastric cancer with MEK1 gene mutations.
Sogabe S; Togashi Y; Kato H; Kogita A; Mizukami T; Sakamoto Y; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Tomida S; Yasuda T; Takeyama Y; Okuno K; Nishio K
Mol Cancer Ther; 2014 Dec; 13(12):3098-106. PubMed ID: 25253779
[TBL] [Abstract][Full Text] [Related]
14. Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase.
Mallon R; Feldberg L; Kim S; Collins K; Wojciechowicz D; Kohler C; Kovacs D; Discafani C; Zhang N; Wu B; Floyd B; Powell D; Berger D
Mol Cancer Ther; 2004 Jun; 3(6):755-62. PubMed ID: 15210862
[TBL] [Abstract][Full Text] [Related]
15. Novel changes in NF-{kappa}B activity during progression and regression phases of hyperplasia: role of MEK, ERK, and p38.
Chandrakesan P; Ahmed I; Anwar T; Wang Y; Sarkar S; Singh P; Peleg S; Umar S
J Biol Chem; 2010 Oct; 285(43):33485-33498. PubMed ID: 20710027
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.
Yoshida T; Kakegawa J; Yamaguchi T; Hantani Y; Okajima N; Sakai T; Watanabe Y; Nakamura M
Oncotarget; 2012 Dec; 3(12):1533-45. PubMed ID: 23237773
[TBL] [Abstract][Full Text] [Related]
17. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Miller CR; Oliver KE; Farley JH
Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
[TBL] [Abstract][Full Text] [Related]
18. Isorhamnetin suppresses skin cancer through direct inhibition of MEK1 and PI3-K.
Kim JE; Lee DE; Lee KW; Son JE; Seo SK; Li J; Jung SK; Heo YS; Mottamal M; Bode AM; Dong Z; Lee HJ
Cancer Prev Res (Phila); 2011 Apr; 4(4):582-91. PubMed ID: 21330379
[TBL] [Abstract][Full Text] [Related]
19. Sef downregulation by Ras causes MEK1/2 to become aberrantly nuclear localized leading to polyploidy and neoplastic transformation.
Duhamel S; Hébert J; Gaboury L; Bouchard A; Simon R; Sauter G; Basik M; Meloche S
Cancer Res; 2012 Feb; 72(3):626-35. PubMed ID: 22298595
[TBL] [Abstract][Full Text] [Related]
20. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
Holt SV; Logié A; Odedra R; Heier A; Heaton SP; Alferez D; Davies BR; Wilkinson RW; Smith PD
Br J Cancer; 2012 Feb; 106(5):858-66. PubMed ID: 22343622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
